“…With a large number of PPIs involving 14-3-3 (Johnson et al, 2010) identified as potential therapeutic targets, this approach can determine the structures of these complexes in a straightforward manner and therefore will assist greatly in the first steps of structure-based drug development, producing crystals from which structures can easily be determined and which can be used as a basis for soaking fragments/compounds (both inhibitors and stabilizers of 14-3-3 PPIs; Stevers et al, 2018;Ballone et al, 2018). So far, discovered small-molecule ligands of 14-3-3 proteins display a considerable degree of chemical diversity, ranging from fragments (Sijbesma et al, 2017(Sijbesma et al, , 2019 and 'classical' small molecules to supramolecular ligands (Bier et al, 2013(Bier et al, , 2017de Vink et al, 2017) and natural products (Andrei, de Vink et al, 2018;Kaplan et al, 2020;Molzan et al, 2013) to modified peptides (Glas et al, 2014;Andrei, Meijer et al, 2018;Milroy et al, 2015;Andrei et al, 2019), with most requiring specific co-crystallization conditions. Our new method may also enable a faster and more modular elucidation of these ligands in the future.…”